A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.

Source:http://linkedlifedata.com/resource/pubmed/id/21482699

J. Exp. Med. 2011 May 9 208 5 973-86

Download in:

View as

Triples

General Info

PMID
21482699